O efeito da FNDC5 e Irisina em linhagens de células de câncer de mama MCF-7 e MDA-MB-231

• Ano de defesa: 2023
• Autor(a) principal: Fortes Junior, Pedro Florencio da Cunha
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; BR; Mestrado em Bioquímica; Centro de Ciências da Saúde; UFES; Programa de Pós-Graduação em Bioquímica
• Palavras-chave em Português: Câncer de mama; MCF-7; MDA-MB-231; Miociona; FNDC5; Irisina; subject.br-rjbn; Farmacologia Bioquímica e Molecular
• Link de acesso: http://repositorio.ufes.br/handle/10/17286

Cancer is the second most prevalent disease and causes of deaths worldwide. Among the most prevalent cancers among women is breast cancer; It is estimated that 2.3 million new cases appear annually around the world. In this context, there is growing concern in the scientific field about the advancement of this disease. A myokine was discovered in 2012 that appears to reduce the proliferation of cancer cells, increasing the expression of pro-apoptotic proteins, decreasing the action of cell synthesis and proliferation mechanisms and other pro-inflammatory factors, in addition to regulating energy homeostasis. The objective of this work was to evaluate the effect of FNDC5 and Irisin molecules on human breast cancer lines. The recombinant molecules Irisin (glycosylated) and FNDC5 were used. The molecules were evaluated at concentrations of 0,625 nmol/L, 1,25 nmol/L, 2.5 nmol/L, 5 nmol/L, 10 nmol/L, 20 nmol/L and 40 nmol/L and the cells were treated48 hours. After this period, the MTT reagent was added at a concentration of 5 mg/mL, and incubation was carried out for 3 hours. After this period, the supernatant was discarded, 100 μl of DMSO reagent was added to all wells and, after 15 minutes, the absorbances were read at 540 nm. The estimated values of the 50% inhibitory concentration of cell proliferation (IC50) were calculated. The calculations were carried out using the GraphPad Prism software in version 8.0. Regarding the data from the MTT experiments, for normal data, one-way ANOVA with Dunnett's post hoc was used, and non-normal data were analyzed by Kruskall-Walli with Dunn's post hoc. The results showed that Irisin exerted cytotoxicity on the MDA-MB-231 strain at concentrations of 1.25 nmol/L (p<0.01), 5 nmol/L (p<0.01), 10 nmol/L (p< 0.0001), 20 nmol/L (p<0.05) and 40 nmol/L (p<0.01) with MCV values reaching 77.66%, 78.75%, 67.25%, 77, 83% and 75.5% respectively. In the MCF-7 line treated with Irisin, a reduction in viability was observed at a concentration of 2.5 nmol/L (p<0.05), a concentration at which the observed MCV was 83.58%. In turn, the FNDC5 molecule did not cause a statistically significant reduction in metabolic cell viability in the tested lines. Our data show that irisin can play an important role in treatment, with deleterious effects on the cell viability of cancer cells.